A population-based study of the outcome for patients with first relapse of Hodgkin's lymphoma

European Journal of Haematology

Volumn 68, Issue 4, 2002, Pages 225-232

  Amini, Rose Marie ^a   Glimelius, Bengt ^a   Gustavsson, Anita ^b   Ekman, Tor ^c   Erlanson, Martin ^d   Haapaniemi, Eva ^e   Enblad, Gunilla ^a  

^a UPPSALA UNIVERSITY HOSPITAL   (Sweden)

^b LUND UNIVERSITY HOSPITAL   (Sweden)

^c SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^d UMEÅ UNIVERSITY HOSPITAL   (Sweden)

^e LINKÖPING UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Hodgkin's lymphoma; Prognostic factors; Relapse; Treatment

Indexed keywords

ANTINEOPLASTIC AGENT; BLEOMYCIN; CHLORMETHINE; DACARBAZINE; DOXORUBICIN; PREDNISONE; PROCARBAZINE; VINBLASTINE; VINCRISTINE;

ADOLESCENT; ADULT; AGE; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER STAGING; CAUSE OF DEATH; CONTROLLED STUDY; FEMALE; FOLLOW UP; HODGKIN DISEASE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; PRIORITY JOURNAL; PROGNOSIS; RELAPSE; SALVAGE THERAPY; SECOND CANCER; SURVIVAL RATE; SWEDEN; TREATMENT OUTCOME;

ADOLESCENT; ADULT; COMBINED MODALITY THERAPY; FEMALE; HODGKIN DISEASE; HUMANS; MALE; MIDDLE AGED; RECURRENCE; SURVIVAL ANALYSIS; SWEDEN;

EID: 0036288749     PISSN: 09024441     EISSN: None     Source Type: Journal    
DOI: 10.1034/j.1600-0609.2002.01565.x     Document Type: Article

References (32)

1. Outcome of patients with Hodgkin's disease failing after primary MOPP-ABVID
2. Conventional-dose salvage combination chemotherapy in patients relapsing with Hodgkin's disease after combination chemotherapy: The low probability for cure
3. Late relapses in Hodgkin's disease: Outcome of patients relapsing more than twelve months after primary chemotherapy
4. Treatment of relapsed Hodgkin's disease: Strategies and prognostic factors
5. The management of Hodgkin's disease in relapse after primary radiation therapy
6. Survival analysis of patients with clinical stages I or II Hodgkin's disease who have relapsed after initial treatment with radiotherapy alone
7. Prognostic factors for patients with Hodgkin's disease in first relapse
8. Influence of more extensive radiotherapy and adjuvant chemotherapy on long-term outcome of early-stage Hodgkin's disease: A meta-analysis of 23 randomized trials involving 3888 patients
9. Favourable prognosis after late relapse of Hodgkin's disease
10. Hodgkin's disease
11. Hodgkin's disease
12. Primary refractory Hodgkin's disease
13. Prognostic factors for disease progression in advanced Hodgkin's disease: An analysis of patients aged under 60 years showing no progression in the first 6 months after starting primary chemotherapy
14. Late complications after Hodgkin's disease
15. Treatment of Hodgkin's disease: The Swedish National Health Care Programme experience
16. Report on the Committee on Hodgkin's disease staging
17. Treatment outcome in patients younger than 60 years with advanced stages (IIB-IV) of Hodgkin's disease: The Swedish National Health Care Programme experience
18. Methyl-GAG, ifosfamide, methotrexate and etoposide (MIME) as salvage therapy for Hodgkin's disease: A prospective study
19. Methyl-GAG, ifosfamide, methotrexate and etoposide (MIME) as salvage therapy for Hodgkin's disease and non-Hodgkin's lymphoma
20. Prognostic factors in Hodgkin's disease
21. A prognostic score for advanced Hodgkin's disease
22. Treatment of early and intermediate stages of supradiaphragmatic Hodgkin's disease. The Swedish National Health Care Program Experience
23. Chemotherapy-radiotherapy association in Hodgkin's disease, clinical stages IA, II2A. Results of a prospective clinical trial with 166 patients
24. MOPP chemotherapy plus irradiation for Hodgkin's disease, stages IA to IIIB. Long term results of the prospective trial H72 (1972-76, 334 patients)
25. Clinical stage I and II Hodgkin's disease: Long-term results of therapy without laparatomy - Experience at one institution
26. Involved-field radiation is as effective as extended field radiation following chemotherapy for intermediate stage Hodgkin's disease expecting a reduction of long-term side effects: Interim analysis of the HD8 trial (GHSG)
27. A systematic overview of chemotherapy effects in Hodgkin's disease
28. Does radiotherapy have to justify its use in Hodgkin's disease?
29. Index of pretreatment intensity predicts outcome of high-dose chemotherapy and autologous progenitor cell transplantation in chemosensitive relapse of Hodgkin's disease
30. The case for and against high dose therapy with stem cell rescue for early poor prognosis Hodgkin's disease in first remission
31. Dose intensification with autologous bone-marrow transplantation in relapsed and resistant Hodgkin's disease: Results of a BNLI randomised trial
32. Prognostic factors and treatment outcome in primary progressive Hodgkin lymphoma: A report from the German Hodgkin Lymphoma Study Group